Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalCardiologyRehabilitationTrial Update

Mobile Technology May Enhance Cardiac Rehabilitation Participation Post-Acute Coronary Syndrome

The exploration of mobile technology in cardiac rehabilitation could significantly enhance patient participation rates, which are currently below 30%. If successful, this approach may disrupt traditional rehabilitation models, necessitating a strategic response from pharma companies involved in cardiac care.

Published: July 1, 2026
Updated: July 1, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Rehabilitation
Asset: Mobile
Indication: patients post-acute coronary syndrome
Trial SummaryCLN

Phase III

patients post-acute coronary syndrome

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The exploration of mobile technology in cardiac rehabilitation could significantly enhance patient participation rates, which are currently below 30%. If successful, this approach may disrupt traditional rehabilitation models, necessitating a strategic response from pharma companies involved in cardiac care.

Why it matters

The exploration of mobile technology in cardiac rehabilitation could significantly enhance patient participation rates, which are currently below 30%. If successful, this approach may disrupt traditional rehabilitation models, necessitating a strategic response from pharma companies involved in cardiac care.

What changed

Trial Update

Analysis

A study is exploring the use of mobile technology to improve participation in cardiac rehabilitation after acute coronary syndrome, where current utilization is below 30%.

The exploration of mobile technology in cardiac rehabilitation could significantly enhance patient participation rates, which are currently below 30%. If successful, this approach may disrupt traditional rehabilitation models, necessitating a strategic response from pharma companies involved in cardiac care.

Monitor results from the trial to assess the efficacy of mobile technology compared to traditional rehabilitation methods.

Related companies & assets

Assets

  • Mobile →

Sources & Humanexa intelligence

Source links

  • Mobile Technology May Enhance Cardiac Rehabilitation Participation Post-Acute Coronary Syndrome ↗

Related Humanexa pages

  • Mobile Technology May Enhance Cardiac Rehabilitation Participation Post-Acute Coronary Syndrome →

Related signals

Trial SummaryCLN

Phase III

Infectious Disease / Vaccines

Status

Positive

Signal Score

8.2

Clinicalhigh signal

Study shows no autoantibody induction post-BNT162b2 boost in CoronaVac-primed individuals

No significant changes in autoantibody profiles were observed 26 weeks after BNT162b2 boosting in individuals primed with CoronaVac.

July 4, 2026Read signal →
Trial SummaryCLN

Phase III

Abramson Cancer Center

Status

Initiated

Signal Score

8.2

Clinicalhigh signal

Study on Blood Markers for Early Detection of Pancreatic Cancer Initiated

A study is underway to collect blood samples for detecting potential pancreatic cancer markers and creating a biobank.

July 4, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.